Skip to content

A Randomized, Double-Blind, Parallel-Controlled, Multi-Center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Children's Xiaochaihu Granules in Treating Pediatric Gastrointestinal Cold with Shaoyang Syndrome Pattern

A Randomized, Double-Blind, Parallel-Controlled, Multi-Center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Children's Xiaochaihu Granules in Treating Pediatric Gastrointestinal Cold with Shaoyang Syndrome Pattern

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001970
Enrollment
Unknown
Registered
2025-10-22
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Gastrointestinal Cold with Shaoyang Syndrome Pattern

Interventions

Control group:10% Children's Xiaochaihu Granules (very low-dose)
Treatment group:Children's Xiaochaihu Granules

Sponsors

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine?
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 13 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for pediatric gastrointestinal cold; (2) Conform to the pattern differentiation criteria of Shaoyang syndrome pattern; (3) Aged 3 to 13 years (<14 years); (4) Maximum axillary temperature =37.3°C (99.1°F) within 24 hours prior to randomization; (5) Disease duration =48 hours prior to randomization; (6) The informed consent process complies with regulations, and participants aged =8 years must sign the "Informed Consent Form" together with their guardians.

Exclusion criteria

Exclusion criteria: (1) Patients definitively diagnosed with influenza, rotavirus enteritis, or other specific diseases; (2) Patients with frequent vomiting leading to difficulty in taking medication, or severe diarrhea causing moderate to severe dehydration; (3) Patients with elevated white blood cell count (WBC), absolute neutrophil count (ANC), and C-reactive protein (CRP), deemed by the investigator to indicate bacterial infection; (4) Patients with comorbid or complicated severe malnutrition, rickets, or severe diseases/impairments of the cardiovascular, cerebral, hepatic, renal, or hematopoietic systems; (5) Patients with a history of epilepsy or febrile seizures; (6) Patients with known allergy to the investigational product or its components; (7) Patients considered by the investigator as unsuitable for participation.

Design outcomes

Primary

MeasureTime frame
Clinical recovery rate/time;Complete fever resolution rate/time;Marked efficacy rate of major symptoms;Response rate of TCM syndrome efficacy/scores;Resolution rate of individual symptoms;

Countries

China

Contacts

Public ContactPingRong

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine?

2467755681@qq.com18087296259

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026